



Trodelvy[®] (sacituzumab govitecan-hziy)

Incidence and Management of Rash in mBC

This document is provided in response to your request for information about Trodelvy[®] (sacituzumab govitecan-hziy [SG]) and the incidence and management of rash.

This document summarizes data for SG monotherapy (10 mg/kg IV on Days 1 and 8 of a 21-day treatment cycle) from phase 2 and 3 clinical studies, with a focus on patients with mBC.

Gilead continually assesses safety data from all sources for unidentified drug reactions and updates the product label information accordingly to reflect the safety profile of SG. Because case reports of potential adverse reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish causal relationship to drug exposure. For this reason, Gilead does not provide information from post-marketing spontaneous reports.

Some data may be outside of the US FDA-approved prescribing information. In providing this data, Gilead Sciences, Inc. is not making any representation as to its clinical relevance or to the use of any Gilead product(s). For information about the approved conditions of use of any Gilead drug product, please consult the FDA-approved prescribing information.

The full indication, important safety information, and boxed warnings for neutropenia and diarrhea are available at:

www.gilead.com/-/media/files/pdfs/medicines/oncology/trodelvy/trodelvy_pi.

Relevant Product Labeling¹

Dosage and Administration

Important use information and premedication

Premedication

Prior to each dose of SG, premedication for prevention of infusion reactions is recommended. Premedicate with antipyretics, histamine 1 and histamine 2 blockers prior to infusion, and corticosteroids may be used for patients who had prior infusion reactions.

Dosage modifications for adverse reactions

Management of adverse reactions may require temporary interruption, dose reduction, or permanent discontinuation of SG as described in Tables 1 and 2. Do not re-escalate the SG dose after a dose reduction for adverse reactions has been made.

Table 1. Dosage Reduction Levels¹

Dose Reduction ^a	Dosage and Schedule
First	Reduce to 7.5 mg/kg
Second	Reduce to 5 mg/kg

^aPermanently discontinue SG in patients unable to tolerate 5 mg/kg.

The recommended dosage modifications for infusion-related reactions (IRRs) are provided in Table 2.

Table 2. Dose Modifications for IRRs¹

Severity	Dose Modification
Grade 1–3 IRRs	Slow infusion rate or interrupt the infusion
Grade 4 IRRs	Permanently discontinue SG

Contraindications

SG is contraindicated in patients who have experienced a severe hypersensitivity reaction to SG.

Warnings and Precautions

Hypersensitivity and IRRs

SG can cause serious hypersensitivity reactions including life-threatening anaphylactic reactions. Severe signs and symptoms included cardiac arrest, hypotension, wheezing, angioedema, swelling, and skin reactions.

Closely monitor patients for hypersensitivity and infusion-related reactions during each SG infusion and for at least 30 minutes after completion of each infusion.

Incidence and Management of Rash in SG Clinical mBC Studies

Premedication and Management of SG-Related Toxicities

Premedication for the prevention of IRRs such as rash included antihistamines that were to be administered before each SG infusion. Corticosteroids (hydrocortisone 50 mg or equivalent [oral or IV]) could also be administered prior to subsequent infusions if the patient experienced an IRR with a previous infusion.²⁻⁵

SG-associated toxicities were assessed and managed in accordance with standard clinical/institutional practices and accepted treatment guidelines.²⁻⁵

ASCENT Study in 2L+ mTNBC

Treatment durations and rash-related safety data for the ASCENT study are shown in Table 3. No frequency data are available for pre-infusion medication use of corticosteroids or systemic antihistamines for the prevention of IRRs in either treatment group.⁶

Table 3. ASCENT: Treatment Duration and Rash-Related Safety Data in OSP^{6,7}

	SG (n=258)	TPC (n=224)
Treatment duration, median (range), mo	4.4 (0.03–22.9)	1–1.6 ^a
Any-grade TRAE of rash of any kind, n (%)	22 (9)	3 (1)
Grade 3 TRAE of rash, n	1	1
Any-grade TEAE of rash, n (%)	32 (12)	12 (5)

Abbreviations: OSP=overall safety population; TPC=treatment of physicians' choice; TRAE=treatment-related adverse event.

^aTreatment durations for TPC agents: eribulin, 1.6 (0.03–15.3) mo; vinorelbine, 1 (0.03–11.5) mo; gemcitabine, 1.4 (0.2–8.1) mo; and capecitabine, 1.2 (0.3–10.6) mo. Data were unavailable for 6 patients who received capecitabine.

TROPiCS-02 Study in Pretreated HR+/HER2- mBC

IRRs were defined as symptoms, including rash, that occurred within the first 6 hours after SG administration and could occur at any cycle.³ Treatment durations and pre-infusion use of medications are shown in Table 4. Rash was not among the any-grade TRAEs with a reported incidence of $\geq 10\%$.⁸

Table 4. TROPiCS-02: Treatment Duration and Pre-Infusion Medications⁹⁻¹²

	SG (n=268)	TPC (n=249)
Treatment duration, median (range), mo	4.1 (0.03–24.2)	2.3 (0.03–22.3) ^a
Pre-infusion/concomitant use of medication, ^b %	Corticosteroids	54
	Systemic antihistamines	72

^aTreatment durations for TPC agents: eribulin, 3.4 (0.03–18.3) mo; vinorelbine, 1.2 (0.03–8.1) mo; gemcitabine, 1.5 (0.03–22.3) mo; and capecitabine, 4.5 (0.2–12.9) mo.

^bData are from the ITT population (N=543). Use of pre-infusion medication in the OSP was not reported.⁸

IMMU-132-01 Study in Metastatic Epithelial Cancer

IMMU-132-01 investigated the safety and efficacy of SG in patients with metastatic epithelial cancers, including mTNBC and HR+/HER2- mBC; 402 of the 495 patients in the OSP received SG 10 mg/kg.⁴ Treatment duration, rash-related safety data, and pre-infusion medications are shown in Table 5.

Table 5. IMMU-132-01 (OSP): Treatment Duration, Treatment-Related Rash, and Pre-Infusion Medications^{4,13}

	SG (n=402)
Treatment duration, median (range), mo	3.7 (0–55.2)
TRAE of rash, n (%)	49 (12)
Pre-infusion medications, %	Systemic corticosteroids
	Antihistamines

In the mTNBC cohort (n=108), a total of 30 (28%) and 2 (2%) patients experienced any-grade and Grade 3 rash (which could include maculopapular rash, generalized rash, dermatitis acneiform, and skin disorder), respectively. The median treatment duration in this cohort was 5.1 mo.¹⁴ In the HR+/HER2- mBC cohort (n=54), rash was not among the any-grade or Grade 3 TRAEs reported in $\geq 15\%$ or $\geq 5\%$ of patients, respectively. The median (range) treatment duration in this cohort was 4.6 (0–29.4) mo.¹⁵

References

1. TRODELVY® Gilead Sciences Inc. Trodelvy (sacituzumab govitecan-hziy) for injection, for intravenous use. U.S. Prescribing Information. Foster City, CA.
2. Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer [Protocol]. *N Engl J Med.* 2021;384(16):1529-1541.
3. Rugo HS, Bardia A, Marme F, et al. Sacituzumab govitecan in hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer [Protocol]. *J Clin Oncol.* 2022;40(29):3365-3376.
4. Bardia A, Messersmith WA, Kio EA, et al. Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial. *Ann Oncol.* 2021;32(6):746-756.
5. Cortés J, Punie K, Barrios C, et al. Sacituzumab govitecan in untreated, advanced triple-negative breast cancer [Protocol]. *N Engl J Med.* 2025;393(19):1912-1925.
6. Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. *N Engl J Med.* 2021;384(16):1529-1541.
7. Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer [Supplementary Appendix]. *N Engl J Med.* 2021;384(16):1529-1541.
8. Rugo HS, Bardia A, Marme F, et al. Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer [Supplementary Appendix] *J Clin Oncol.* 2022;40(29):3365-3376.
9. Rugo HS, Bardia A, Marmé F, et al. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. *The Lancet.* 2023;402(10411):1423-1433.
10. Rugo HS, Bardia A, Marmé F, et al. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial [Supplementary Appendix]. *The Lancet.* 2023;402(10411):1423-1433.
11. Rugo HS, Bardia A, Marme F, et al. Sacituzumab govitecan in hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. *J Clin Oncol.* 2022;40(29):3365-3376.
12. Rugo HS, Bardia A, Marme F, et al. Sacituzumab govitecan in hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer [Supplementary Appendix]. *J Clin Oncol.* 2022;40(29):3365-3376.
13. Bardia A, Messersmith WA, Kio EA, et al. Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial [Supplementary Appendix]. *Ann Oncol.* 2021;32(6):746-756.
14. Bardia A, Mayer IA, Vahdat LT, et al. Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer. *N Engl J Med.* 2019;380(8):741-751.
15. Kalinsky K, Diamond JR, Vahdat LT, et al. Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial. *Ann Oncol.* 2020;31(12):1709-1718.

Product Label

For the full indication, important safety information, and boxed warning(s), please refer to the Trodelvy US Prescribing Information available at:

www.gilead.com/-/media/files/pdfs/medicines/oncology/trodelvy/trodelvy_pi.

Follow-Up

For any additional questions, please contact Trodelvy Medical Information at:

☎ 1-888-983-4668 or 🌐 www.askgileadmedical.com

Adverse Event Reporting

Please report all adverse events to:

Gilead Global Patient Safety ☎ 1-800-445-3235, option 3 or
🌐 www.gilead.com/utility/contact/report-an-adverse-event

FDA MedWatch Program by ☎ 1-800-FDA-1088 or ✉ MedWatch, FDA, 5600 Fishers Ln, Rockville, MD 20852 or 🌐 www.accessdata.fda.gov/scripts/medwatch

Data Privacy

The Medical Information service at Gilead Sciences may collect, store, and use your personal information to provide a response to your medical request. We may share your information with other Gilead Sciences colleagues to ensure that your request is addressed appropriately. If you report an adverse event or concern about the quality of a Gilead or Kite product, we will need to use the information you have given us in order to meet our regulatory requirements in relation to the safety of our medicines.

It may be necessary for us to share your information with Gilead's affiliates, business partners, service providers, and regulatory authorities located in countries other than your own. Gilead Sciences has implemented measures to protect the personal information you provide. Please see the Gilead Privacy Statement (www.gilead.com/privacy-statements) for more information about how Gilead handles your personal information and your rights. If you have any further questions about the use of your personal information, please contact gilead.privacy@gilead.com.

TRODELVY, GILEAD, and the GILEAD logo are registered trademarks of Gilead Sciences, Inc., or its related companies.
© 2026 Gilead Sciences, Inc.